NCT07238023 Promoting Active Living Among People With Metastatic Breast Cancer
| NCT ID | NCT07238023 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Oklahoma |
| Condition | Metastatic Invasive Breast Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 38 participants |
| Start Date | 2026-02-27 |
| Primary Completion | 2026-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 38 participants in total. It began in 2026-02-27 with a primary completion date of 2026-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Individuals with metastatic breast cancer are living longer but often face persistent fatigue, functional decline, and psychological distress. Physical activity is generally safe for this population and may alleviate symptom burden. Yet, limited interventions are tailored to the unique and needs and preferences of this population. This study aims to evaluate the acceptability and feasibility of a mindfulness- and acceptance-based physical activity program designed to support mental, social, and spiritual well-being among people with metastatic breast cancer. A single group, pretest-posttest trial (N=38) will be conducted to inform scalable strategies to promote active living and enhance quality of life among people with advanced cancer.
Eligibility Criteria
Inclusion Criteria: * having been diagnosed with metastatic breast cancer * medical clearance from healthcare provider to participate in this study * life expectancy of at least 6 months as per the participant's healthcare provider * Eastern Cooperative Oncology Group performance status of or 0 or 1 * being willing and able to use a smartphone and web interface with or without assistance; if assistance is needed, it must be readily available * adequate visual and hearing acuity to use a smartphone and web interface as indicated by self-report * adequate motor capacity to use a smartphone and web interface as indicated by self-report * willingness to download and use study-specific app(s), the Fitbit mobile application (this requires use of a Google Gmail account), and other mobile applications for study purposes as needed * completed baseline survey Exclusion Criteria: * contraindications to physical activity (e.g., uncontrolled hypertension or cardiac disease noted by the patient's treating healthcare provider) * presence of bone metastases deemed unstable by the treating healthcare provider. * untreated brain metastases * history of dementia or other major neurocognitive disorder * received a diagnosed of Major Depressive Disorder within the previous 6 months * received a diagnosis of a major psychiatric conditions such as bipolar disorder, psychosis, schizophrenia, or alcoholism that could affect the ability to understand and/or complete the study * currently hospitalized * enrolled in hospice * inability to speak, read, and write in English at the 7th grade level
Contact & Investigator
Michael C Robertson, MPH, PhD
PRINCIPAL INVESTIGATOR
University of Oklahoma
Frequently Asked Questions
Who can join the NCT07238023 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying Metastatic Invasive Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07238023 currently recruiting?
Yes, NCT07238023 is actively recruiting participants. Contact the research team at Michael-Robertson@ou.edu for enrollment information.
Where is the NCT07238023 trial being conducted?
This trial is being conducted at Oklahoma City, United States.
Who is sponsoring the NCT07238023 clinical trial?
NCT07238023 is sponsored by University of Oklahoma. The principal investigator is Michael C Robertson, MPH, PhD at University of Oklahoma. The trial plans to enroll 38 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.